Authorizing Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy11514

POLICY TYPE  Policy document
LAST REVIEWED  2020-02-29
DATE  2015-02-28
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)
https://policybase.cma.ca/link/policy11297

POLICY TYPE Parliamentary submission
DATE 2014-10-28
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-2 An Act to amend the Controlled Drugs and Substances Act ( Respect for Communities Act)
https://policybase.cma.ca/link/policy11519

POLICY TYPE Parliamentary submission
DATE 2015-05-14
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-17 An Act to amend the Food and Drugs Act
https://policybase.cma.ca/link/policy11196

POLICY TYPE
Parliamentary submission

DATE
2014-06-11

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13723

POLICY TYPE  Parliamentary submission
DATE  2017-08-18
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13861

POLICY TYPE          Parliamentary submission
DATE               2018-04-18
TOPICS            Pharmaceuticals, prescribing, cannabis, drugs

Documents

Canada’s lower-risk cannabis use guidelines (LRCUG)
https://policybase.cma.ca/link/policy13726

POLICY TYPE          Policy endorsement
DATE               2017-05-26
TOPICS            Pharmaceuticals, prescribing, cannabis, drugs

Documents
Canadian Medical Association submission to the Standing Senate Committee on Banking, Trade and Commerce: Higher rate now: Why excise tax on tobacco is long overdue for an increase

https://policybase.cma.ca/link/policy11129

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Parliamentary submission</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2014-05-15</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Health care and patient safety, Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
</tbody>
</table>

**Documents**

- [Higher rate now: Why excise tax on tobacco is long overdue for an increase](https://policybase.cma.ca/link/policy11129)
Cannabis for Medical Purposes
https://policybase.cma.ca/link/policy10045

POLICY TYPE
Policy document

LAST REVIEWED
2019-03-03

DATE
2010-12-04

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA POLICY

Cannabis for Medical Purposes

The Canadian Medical Association (CMA), recognizes the unique requirements of those individuals suffering from terminal illnesses or chronic diseases for which conventional therapies have not been effective and remain severely limited (i.e. opioids).

The CMA supports further research into the use of cannabis for medical purposes, in order to determine its potential benefits and risks in these contexts. The CMA believes that the use of cannabis for medical purposes should be subject to the same regulatory framework as other prescription drugs.

The CMA recommends that the following recommendations be considered:

1. Support further research into the use of cannabis for medical purposes, including clinical trials on the efficacy and safety of different strains and formulations.
2. Develop a regulatory framework that provides for the safe and effective use of cannabis for medical purposes, including licensing of practitioners and producers.
3. Ensure that patients have access to licensed cannabis products, including access to prescription products for medical purposes.

The CMA calls on the federal government to develop a comprehensive regulatory framework for the use of cannabis for medical purposes, and to ensure that patients have access to licensed products. The CMA also encourages the development of education and training programs for healthcare professionals who may be involved in the provision of cannabis for medical purposes.

The CMA recommends that the following recommendations be considered:

1. Support further research into the use of cannabis for medical purposes, including clinical trials on the efficacy and safety of different strains and formulations.
2. Develop a regulatory framework that provides for the safe and effective use of cannabis for medical purposes, including licensing of practitioners and producers.
3. Ensure that patients have access to licensed cannabis products, including access to prescription products for medical purposes.

The CMA calls on the federal government to develop a comprehensive regulatory framework for the use of cannabis for medical purposes, and to ensure that patients have access to licensed products. The CMA also encourages the development of education and training programs for healthcare professionals who may be involved in the provision of cannabis for medical purposes.

The CMA recommends that the following recommendations be considered:

1. Support further research into the use of cannabis for medical purposes, including clinical trials on the efficacy and safety of different strains and formulations.
2. Develop a regulatory framework that provides for the safe and effective use of cannabis for medical purposes, including licensing of practitioners and producers.
3. Ensure that patients have access to licensed cannabis products, including access to prescription products for medical purposes.

The CMA calls on the federal government to develop a comprehensive regulatory framework for the use of cannabis for medical purposes, and to ensure that patients have access to licensed products. The CMA also encourages the development of education and training programs for healthcare professionals who may be involved in the provision of cannabis for medical purposes.
CMA Recommendations on Vaccine Equity and Intellectual Property

https://policybase.cma.ca/link/policy14476

POLICY TYPE  Parliamentary submission
DATE  2022-05-13
TOPICS  Ethics and medical professionalism
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents

CMA Recommendations on Vaccine Equity and Intellectual Property

House of Commons Standing Committee on Foreign Affairs and International Development
May 11, 2022
CMA Response: Health Canada's Medical Marijuana Regulatory Proposal
https://policybase.cma.ca/link/policy10702

POLICY TYPE
Parliamentary submission

DATE
2013-02-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA response to patented medicines regulations consultations
https://policybase.cma.ca/link/policy13690

POLICY TYPE
Response to consultation

DATE
2017-06-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA's Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts
https://policybase.cma.ca/link/policy13641

POLICY TYPE
Parliamentary submission

DATE
2017-04-07

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13918

**POLICY TYPE**  Parliamentary submission

**DATE**  2018-02-15

**TOPICS**  Pharmaceuticals, prescribing, cannabis, drugs

Health care and patient safety

**Documents**

![CMA Submission: CMA's Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

Submission to the House of Commons Standing Committee on Health

February 15, 2018]
CMA’s Response to Health Canada’s Public Consultation Guide to New Authorities in reference to Bill C-17, Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law)

https://policybase.cma.ca/link/policy11599

POLICY TYPE: Response to consultation

DATE: 2015-06-08

TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Submission to the Senate Committee on Social Affairs, Science and Technology as part of its study on prescription pharmaceuticals: Federal levers to address unintended consequences of prescription pharmaceuticals and support public health, quality care, and patient safety

https://policybase.cma.ca/link/policy11125

POLICY TYPE
Parliamentary submission

DATE
2014-03-26

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
CMA’s Submission to the Senate Committee on Social Affairs, Science and Technology – Prescription Pharmaceuticals in Canada: The Post-Approval Monitoring of Prescription Pharmaceuticals

https://policybase.cma.ca/link/policy10631

POLICY TYPE
Parliamentary submission

DATE
2012-10-24

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents